sr141716 has been researched along with malondialdehyde in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dragutinović, V; Ješić Vukićević, R; Jorgačević, B; Mladenović, D; Ninković, M; Radosavljević, T; Vatazević, A; Vesković, M; Vučević, D | 1 |
| Cao, S; Guo, H; Li, P; Li, Q; Li, S; Lin, Q; Sun, S; Wang, Y; Xia, Y; Yang, N; Zhang, W; Zheng, Z; Zhu, M | 1 |
2 other study(ies) available for sr141716 and malondialdehyde
| Article | Year |
|---|---|
Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease.
Topics: Animals; Cannabinoid Receptor Antagonists; Diet, High-Fat; Disease Models, Animal; Glutathione; Liver; Male; Malondialdehyde; Metals; Mice; Mice, Inbred C57BL; Nitrates; Nitrites; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Piperidines; Pyrazoles; Rimonabant; Superoxide Dismutase | 2015 |
Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism.
Topics: Cell Death; Fatty Acids; Ferroptosis; Glutathione; Humans; Iron; Lipid Metabolism; Lipid Peroxides; Malondialdehyde; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phospholipids; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Receptor, Cannabinoid, CB1; Rimonabant; Stearoyl-CoA Desaturase; Triple Negative Breast Neoplasms | 2022 |